Patient P-03251
Therapy response
Stable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
73%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S14
- Day 58 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 60 SC-12 recommended — Supportive Compound SC-12
- Day 61 Patient accepted — Started SC-12 in the companion
- Day 62 GI-04 recommended — GI Support Protocol GI-04
- Day 63 Patient accepted — Started GI-04 in the companion
- Day 67 GI symptom burden −13% vs expected — Supportive Compound SC-12
- Day 71 No meaningful change — GI Support Protocol GI-04
- Day 73 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 58.
Primary contributors, last 14 days
- GI instability-18
- Inflammatory activity-11
- Nutritional resilience+11
- Toxicity-9
- Treatment adherence-8
What helped?
- Supportive Compound SC-12Day 60Result: symptom burden −13%
- GI Support Protocol GI-04Day 62Result: no meaningful change
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
68%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 75% showed improvement
- median effect visible after 5 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 66 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 41/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↑45
- WearableResting HR 83 bpm
- Wearable3,527 steps/day
- Inflammatory signalling ↓25
- BloodInflammatory load index 58
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3 · butyrate capacity 41/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 43 ms
- Sleep
- 6.8 h
- Steps
- 2,367
- Resting HR
- 84 bpm
Daily log: GI score 66, nutritional resilience 37, adherence 42.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03293 | 41% | S14 | GI-04 | no change | 41 |
| P-03430 | 41% | S14 | SC-12 | improved | 45 |
| P-03049 | 40% | S14 | GI-04 | improved | 49 |
| P-03037 | 39% | S14 | NP-02 | improved | 43 |
| P-03123 | 39% | S14 | GI-04 | improved | 50 |
| P-03323 | 39% | S14 | GI-04 | improved | 48 |
| P-03003 | 38% | S08 | SC-12 | improved | 53 |
| P-03341 | 37% | S14 | NP-02 | improved | 49 |
| P-03384 | 36% | S01 | — | — | 55 |
| P-03413 | 36% | S14 | ME-01 | improved | 48 |
| P-03444 | 36% | S17 | — | — | 62 |
| P-03146 | 35% | S14 | GI-04 | improved | 53 |